Ongoing trials are testing the combination of FAK inhibition and immune checkpoint inhibition primarily in pancreatic cancers, but this strategy should be applicable to a range of cancer types, particularly those discussed in this review. This evidence concerns the gene PTK2 and familial pancreatic carcinoma.